The Institute for Clinical and Economic Review (ICER) on Thursday, Aug. 15, released its final report on treatments for Duchenne muscular dystrophy (DMD).
ICER reviewed three drugs for DMD: PTC Therapeutics’ Emflaza and Sarepta Therapeutics’ Exondys 51 and golodirsen.
ICER CMO David Rind in a statement said “DMD is a devastating disease.”
“Parent testimony shared throughout the day provided a window into the hope and frustration that families are feeling as new treatments become available,” Rind said.
To read the final report, click here.